TSRL, Inc. enters into an exclusive licensing agreement with The Queen's University of Belfast, Northern Ireland, for the use of their patented hydrogel microneedle for a flu treatment patch

TSRL, Inc. announced today that it has entered into a licensing agreement with The Queen’s University of Belfast (“QUB”), Northern Ireland, for the exclusive use of their patented hydrogel microneedle (“MN”) technology for the development of a MN patch for treatment of the flu. Future uses of the platform with other therapeutics and vaccines can be optioned.

ANN ARBOR, MICHIGAN, May 25, 2021, — TSRL, Inc., announces the continued preclinical development of a transdermal delivery system of zanamivir (Relenza®), a product licensed for the treatment and prevention of the flu. Relenza® is a dry-powder inhalation product that requires twice a day administration. This product is difficult to use, especially for the elderly and young children, and it is contraindicated for patients with pulmonary impairments, who are highly susceptible to the flu.

The transdermal delivery system allows for painless self-administration of a single patch that delivers zanamivir over multiple days. Furthermore, this product allows large numbers of patients to be reached through simplified dosing, including those with respiratory impairments.

TSRL’s CEO, Dr. Elke Lipka, noted, “MN-enabled drug delivery was named #1 in the Top 10 Emerging Technologies of 2020, and represents a game changer in drug delivery convenience, compliance and dosing regimen optimization”.

About TSRL, Inc.:

TSRL, Inc. is a preclinical biotech accelerator. We collaborate with partners in academia and industry to develop early-stage anti-infective therapeutics and drug delivery technologies. In these collaborations, we provide infrastructure, drug development expertise, and access to non-dilutive funding. Our portfolio holds promising lead-stage anti-infective therapeutics. We are actively looking for new technologies and strategic partnerships. More information about TSRL, Inc. and portfolio technologies are available at http://www.tsrlinc.com .